• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Combination of testosterone and vardenafil increases female sexual functioning in sub-primed rats.
【24h】

Combination of testosterone and vardenafil increases female sexual functioning in sub-primed rats.

机译：睾丸激素和伐地那非的组合可增加亚致敏大鼠的雌性功能。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Hypoactive sexual desire disorder (HSDD) is a common problem in women and may have a negative impact on quality of life. A recent clinical study shows an increase in sexual drive of HSDD women after cotreatment of testosterone and vardenafil (phosphodiesterase type 5 inhibitor). AIM: In this study, we investigated the effect of testosterone and vardenafil on sexual activity in female rats. MAIN OUTCOME MEASURES: Proceptive (darts and hops), receptive (lordosis), and paced-mating (percentages after exits and contact-return latencies) behaviors were quantified. METHODS: Ovariectomized female rats, sub-primed with only estradiol and fully primed with estradiol and progesterone, were tested in a paced-mating sex test and sexual behaviors were quantified. The sub-primed rats are thought to model HSDD. The effect of testosterone (100 and 300 microg, subcutaneous [SC]) and vardenafil (10 mg/kg, per os [PO]) alone and testosterone (300 microg, SC) in combination with vardenafil (3 and 10 mg/kg, PO) were tested. We also studied the effects of testosterone (300 microg, SC) + intracerebroventricular (ICV) injections of vardenafil (25 and 50 microg) on sexual activity. RESULTS: No effect of testosterone and vardenafil alone was found, but cotreatment of testosterone and vardenafil (PO) caused a significant increase in proceptive and receptive behavior in the sub-primed female rats. Testosterone and vardenafil did not affect fully primed females. ICV administration of vardenafil combined with systemic testosterone, on the other hand, had no effect on sexual activity in both sub-primed and fully primed female rats. CONCLUSIONS: We conclude that cotreatment of subcutaneous testosterone and oral vardenafil increase sexual activity in sub-primed female rats. Our data supports the human finding that combination treatment of testosterone and vardenafil could be used as a new treatment for women with HSDD.
机译：简介：性欲减退（HSDD）是女性常见的问题，可能对生活质量产生负面影响。最近的一项临床研究表明，睾丸激素和伐地那非（5型磷酸二酯酶抑制剂）联合治疗后，HSDD妇女的性欲增加。目的：在这项研究中，我们调查了睾丸激素和伐地那非对雌性大鼠性活动的影响。主要观察指标：感受性行为（飞镖和蛇麻草），感受性（lordosis）和节律性交配（退出和接触返回潜伏期百分比）行为被量化。方法：将雌性卵巢去卵巢的雌性大鼠仅进行雌二醇充注，并充分雌二醇和孕酮充注，在定步交性试验中对其进行测试，并对性行为进行定量。引发不足的大鼠被认为可以模拟HSDD。单独使用睾丸激素（100和300微克，皮下[SC]）和伐地那非（10 mg / kg，每个口服液[PO]）和结合使用伐地那非（3和10 mg / kg，睾丸激素（300微克，SC）， PO）进行了测试。我们还研究了睾丸激素（300微克，SC）+伐地那非（25和50微克）脑室内注射（ICV）对性活动的影响。结果：没有发现单独使用睾丸激素和伐地那非的作用，但是睾丸激素和伐地那非（PO）的共同治疗导致了初次免疫的雌性大鼠的接受和接受行为显着增加。睾丸激素和伐地那非不影响完全致敏的雌性。另一方面，伐地那非联合全身性睾丸激素的ICV给药对未致敏和完全致敏的雌性大鼠的性活动均无影响。结论：我们得出结论，皮下睾丸激素和口服伐地那非的联合治疗可增加初发雌性大鼠的性活动。我们的数据支持了人类的发现，即睾丸激素和伐地那非的联合治疗可以作为HSDD妇女的新疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号